Vedere Bio ll
Cambridge
About Vedere Bio ll
Vedere is developing cutting-edge gene therapy products to restore functional vision to patients who have suffered vision loss from Inherited Retinal Degenerations (IRDs), as well as other causes of both genetic and non-genetic vision loss. While the vast majority of ocular gene therapies only limit the rate of inevitable vision loss, we aim to restore lost vision regardless of a patient’s underlying genetics or their stage of disease.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $98.0M
- Funding stage: M&A
- Last round: Series A (May 2021)
- Website: vederebio.com
- Phone: (857) 201-2700
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/vedere-bio-ll-131590 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.